Prothena Corp Public SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 5, 2026, 4:07 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedProthena Reports Q3 2026 Net Loss of $0.32 Per Share, Revenue of $0.6 Million, Missing Consensus; Reiterates 2026 Cash Burn Guidance
8-KOct. 29, 2026, 4:03 p.m. ETView on SEC.gov
Termination of a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedProthena Corporation plc: Bristol Myers Squibb terminates PRX019 license, removing $80 million upfront-linked economics and up to $617.5 million in potential milestones
8-KOct. 2, 2026, 4:17 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KAug. 6, 2026, 4:16 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits